|
Lyme and Tick-borne Diseases Work Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
This workgroup involves members from agencies including the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and the National Institutes of Health (NIH) with the purpose of continued coordination and communication of activities, policy updates, events, agency highlights, and other shared interests relating to Lyme disease and other tick-borne diseases.
|
|
Mapping of the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) and International Classification of Disease (ICD) Clinical Terminology
|
Resource Development
|
CDC, OS
|
NLM
|
The US Department of Health and Human Services (HHS) has set a goal for the nationwide implementation of an interoperable health information technology infrastructure to improve the quality and efficiency of healthcare. Achieving this goal will require that key clinical data elements are captured or recorded in detailed, standardized form (using standard vocabularies, codes, and formats) as close to their original sources (patients, healthcare providers, laboratories, diagnostic devices, etc.) as possible. If these standardized clinical data can also be used to generate HIPAA- compliant billing transactions automatically, this will provide another incentive for adoption of clinical data standards. For the automated generation of bills from clinical data to become a reality, robust mappings from standard clinical terminologies to the HIPAA code sets must be created. To support the transition to ICD-10-CM in 2015, a map from SNOMED CT to ICD-10-CM is being created.
|
|
Materials Genome Initiative
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIBIB
|
The Office of Science and Technology Policy(OSTP) chartered this committee to create a new era of policy, resources, and infrastructure that support U.S. institutions in the effort to discover, manufacture, and deploy advanced materials twice as fast, at a fraction of the cost. Led by the National Institute of Standards and Technology(NIST), the National Science Foundation (NSF), and the Department of Defense (DoD) as co-leads it also includes the Food and Drug Administration (FDA), the National Aeronautics and Space Administration (NASA), and the Department of Energy (DoE). 2020 meeting was cancelled due to the COVID-19 pandemic.
|
|
Maternal Health Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA
|
NICHD, NHLBI, NIMHD, OD/DPCPSI/ORWH
|
This internal Department of Health and Human Services (HHS) group was formed in June 2019, with the goal of developing a trans-HHS Action Plan aimed at making the U.S. the safest place in the world to give birth.
|
|
Medical Expenditure Panel Survey (MEPS): Experiences with Cancer Survivorship Supplement
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC
|
NCI
|
The National Cancer Institute (NCI) has collaborated with Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ), and other organizations to provide supplemental funding for the Medical Expenditure Panel Survey (MEPS) to improve the quality of data for estimating the cancer survivorship burden in the United States. Using responses to the National Health Interview Survey(NHIS) question about ever receiving a cancer diagnoses, households with cancer survivors were oversampled for selection in this MEPS supplement. The increased sample of cancer survivors will improve national estimates of the burden of cancer.
|
|
Memorandum of Understanding (MOU) between the FDA Center for Devices and Radiological Health and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
This MOU provides a mechanism for addressing cross-cutting issues related to the development of devices for neurological disorders, from bench science to clinical studies and the Food and Drug Administration (FDA) approval.
|
|
Memorandum of Understanding (MOU) between the FDA/Center for Biologics Evaluation and Research (FDA/CBER) and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
This Memorandum of Understanding (MOU) provides a mechanism for addressing cross-cutting issues related to therapy development for neurological disorders, from bench science to clinical trials and the Food and Drug Administration (FDA) approval and licensure.
|
|
Memorandum of Understanding (MOU) between the FDA/Center for Drug Evaluation and Research (FDA/CDER) and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
This Memorandum of Understanding (MOU) provides a mechanism for addressing cross-cutting issues related to drug therapy development for neurological disorders, from bench science to clinical trials and the Food and Drug Administration (FDA) approval and licensure.
|
|
Microphysiological Systems for Drug Efficacy and Toxicity Testing
|
Research Initiative
|
FDA
|
NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI/ORWH, OD/DPCPSI/OSC
|
The Microphysiological systems initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver, and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine, or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, National Institutes of Health (NIH), in collaboration with the Defense Advanced Research Projects Agency (DARPA) and the US Food and Drug Administration (FDA), is leading this initiative to improve the process for predicting whether drugs will be safe in humans.
|
|
Mind Your Risks
|
Public Education Campaign
|
CDC, CMS
|
NINDS
|
The Mind Your Risks campaign is designed to create awareness and action about the fact that risk factors for stroke, particularly hypertension, may be linked to cognitive impairment and dementia.
|